Close Menu

NEW YORK – Nucleosomes-based testing company VolitionRx announced on Monday that its subsidiary Belgian Volition has entered into an agreement to acquire its epigenetic reagent supplier Octamer for €650,000 ($724,604).

The aggregate purchase price consists of €350,000 in cash and about 73,000 shares of common stock of Volition in exchange for all of Octamer's outstanding shares. Volition said it will issue shares to Octamer in a private placement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.